Impact of pharmacist consultation versus a decision aid on decision making regarding hormone replacement therapy

International Journal of Pharmacy Practice

Volumn 12, Issue 1, 2004, Pages 21-28

  Deschamps, Michelle A ^a   Taylor, Jeff G ^a   Neubauer, Shannan L ^a   Whiting, Susan ^a   Green, Kathryn ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANADA; CLIMACTERIUM; CLINICAL TRIAL; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; FAMILY MEDICINE; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PATIENT SATISFACTION; PHARMACIST; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 9344229262     PISSN: 09617671     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022999     Document Type: Article

References (47)

1. Borgelt L, Umland E. Benefits and challenges of hormone replacement therapy. J Am Pharm Assoc 2000;40:S30-1.
2. Pugh MC, Mullins PM. Hormone replacement therapy. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. Stanford, Connecticut: Appleton & Lange; 2000. p1355-05.
3. Shepherd JE. Effects of estrogen on cognition, mood, and degenerative brain diseases. J Am Pharm Assoc 2001;41: 221-8.
4. Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of nonvertebral fractures: A metaanalysis of randomized trials. JAMA 2001;285:2891-7.
5. Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the Early Postmenopausal Intervention Cohort Study. Ann Intern Med 1999;131:935-42.
6. Hajcsar EE, Hawker G, Bogoch ER. Investigation and treatment of osteoporosis in patients with fragility fractures. Can Med Assoc J 2000;163:819-22.
7. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;276:1389-96.
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33.
10. Calle EE. Hormone replacement therapy and colorectal cancer: interpreting the evidence. Cancer Causes Control 1997;8:127-9.
11. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. The Alzheimer's Disease Cooperative Study. Estrogen replacement therapy for treatment of mild-to-moderate Alzheimer disease: a randomized controlled trial. JAMA 2000;283:1007-15.
12. Mamdani MM, Tu K, van Walraven C, Austin PC, Naylor CD. Postmenopausal estrogen replacement therapy and increased rates of cholecystectomy and appendectomy. Can Med Assoc J 2000;162:1421-4.
13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-59.
14. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449-57.
15. Collins J, Donner A, Allen LH, Adams O. Oestrogen use and survival in endometrial cancer. Lancet 1980;2:961-4.
16. The Canadian consensus conference on menopause and osteoporosis. Hormone replacement therapy and cancer (Part 1). JOGC 1998;20:31-4.
17. Jones JB. Hormone replacement therapy: Women's decision-making process. Soc Work Health Care 1999;28:95-111.
18. Griffiths F. Women's control and choice regarding HRT. Soc Sci Med 1999;49:469-81.
19. Rabin DS, Cipparrone N, Linn ES, Moen M. Why menopausal women do not want to take hormone replacement therapy. Menopause 1999;6:61-7.
20. Armstrong K, Popik S, Guerra C, Ubel PA. Beliefs about breast cancer risk and use of postmenopausal hormone replacement therapy. Med Decis Making 2000;20:308-13.
21. Limouzin-Lamothe M-A. What women want from hormone replacement therapy: results of an international survey. Eur J Obstet Gynecol Reprod Biol 1996;64:S21-4.
22. Schneider HPG. Cross-national study of women's use of hormone replacement therapy (HRT) in Europe. Int J Fertil 1997;42:365-75.
23. France K, Schofield MJ, Lee C. Patterns and correlates of hormone replacement therapy use among middle-aged Australian women. Women's Health 1997;3:121-38.
24. Appling SE, Allen JK, van Zant S, Olsen S, Brager R, Hallerdin J. Knowledge of menopause and hormone replacement therapy use in low-income urban women. J Women's Health Gend Based Med 2000;9:57-64.
25. Nichol MB, McCombs JS, Johnson KA, Spacapan S, Sclar DA. The effects of consultation on over-the-counter medication purchasing decisions. Med Care 1992;30:989-1003.
26. Kaltenbach BL, Joss JD, Phillips BB. Defining and maximizing the use of hormone replacement therapy in postmenopausal women through pharmacist intervention in an ambulatory care setting. ASHP Midyear Clinical Meeting 1998;33 (Dec):133E.
27. Carson JJ. Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults. Am J Health Syst Pharm 1999;56:2319-24.
28. O'Connor AM. Decisional Conflict Scale. 4th ed, 1999. Available at www.lri.ca/programs/ceu/ohdec/default.htm. Accessed March 16, 2000.
29. O'Connor AM, Tugwell P, Wells GA, Elmslie T, Jolly E, Drake E, et al. Randomized trial of a portable self-administered decision aid for postmenopausal women considering long-term preventative hormone therapy. Med Decis Making 1998;18:295-303.
30. Connelly MT, Rusinak D, Livingston W, Raeke L, Inui TS. Patient knowledge about hormone replacement therapy: implications for treatment. Menopause 2000;7:266-72.
31. O'Connor AM. Evaluation Measures. 1999. Available at www.lri.ca/programs/ ceu/ohdec/default.htm. Accessed May 3, 2000.
32. Mingo C, Herman CJ, Jasperse M. Women's stories: Ethnic variations in women's attitudes and experiences of menopause, hysterectomy, and hormone replacement therapy. J Women's Health Gend Based Med 2000;9:S27-38.
33. Meyer D, Leventhal H, Gutmann M. Common-sense models of illness: the example of hypertension. Health Psychol 1985;4:115-35.
34. Holmes-Rovner M, Kroll S, Schmitt N, Rovner DT, Breer L, Rothert M, et al. Patient satisfaction with health care decisions: the Satisfaction with Decision scale. Med Decis Making 1996;16:58-64.
35. Karakoc B, Erenus M. Compliance considerations with hormone replacement therapy. Menopause 1998;5:102-6.
36. Groeneveld FPMJ, Bareman FP, Barentsen R, Dokter HJ, Drogendijk AC, Hoes AW. Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 1998;29:125-31.
37. Vihtamaki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 1999;33:99-105.
38. Little P, Everitt H, Williamson I, Warner G, Moore M, Gould C, et al. Preferences of patients for patient centered approach to consultation in primary care. BMJ 2001;322: 468-72.
39. Rothert ML, Holmes-Rovner M, Rovner DR, Kroll J, Breer L, Talarczyk G, et al. An educational intervention as decision support for menopausal women. Res Nurs Health 1997; 20:377-87.
40. Rostom A, O'Connor A, Tugwell P, Wells G. A randomised trial of a computerized versus an audio-booklet decision aid for women considering post-menopausal hormone replacement therapy. Pat Educ Couns 2002;46:67-74.
41. Kennedy ADM, Sculpher MJ, Coulter A, Dwyer N, Rees M, Abrams KR, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs. JAMA 2002;288:2701-8.
42. Nau DP, Ried LD, Lipowski E. What makes patients think that their pharmacists' services are of value? J Am Pharm Assoc 1997;NS37:91-8.
43. Barnett CW, Nykamp D, Ellington AM. Patient-guided counseling in the community pharmacy setting. J Am Pharm Assoc 2000;40:765-72.
44. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintk CD, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Pharmacotherapy 2000;20:1149-58.
45. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Pharmacotherapy 2000;20:1508-16.
46. Ellis SL, Billups SJ, Malone DC, Carter BL, Covey D, Mason B, et al. Types of interventions made by clinical pharmacists in the IMPROVE study. Pharmacotherapy 2000;20:429-35.
47. Marci CD, Viechnicki MB, Greenspan SL. Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 2000;66:113-8.